Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Impact of lopinavir-ritonavir exposure in HIV-1 infected children and adolescents in Madrid, Spain during 2000-2014.

Rojas Sánchez P, Prieto L, Jiménez De Ory S, Fernández Cooke E, Navarro ML, Ramos JT, Holguín Á; Madrid Cohort of HIV-1 Infected Children and Adolescents Integrated in the Paediatric Branch of the Spanish National AIDS Network (CoRISPe).

PLoS One. 2017 Mar 28;12(3):e0173168. doi: 10.1371/journal.pone.0173168. eCollection 2017.

2.

Antiretroviral therapy: Shifting sands.

Sashindran VK, Chauhan R.

Med J Armed Forces India. 2016 Jan;72(1):54-60. doi: 10.1016/j.mjafi.2015.12.002. Epub 2016 Jan 5. Review.

3.

Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.

Cooper DA, Cordery DV, Zajdenverg R, Ruxrungtham K, Arastéh K, Bergmann F, Neto JL, Scherer J, Chaves RL, Robinson P; study team.

PLoS One. 2016 Jan 5;11(1):e0144917. doi: 10.1371/journal.pone.0144917. eCollection 2016.

4.

High prevalence of PI resistance in patients failing second-line ART in Vietnam.

Thao VP, Quang VM, Day JN, Chinh NT, Shikuma CM, Farrar J, Van Vinh Chau N, Thwaites GE, Dunstan SJ, Le T.

J Antimicrob Chemother. 2016 Mar;71(3):762-74. doi: 10.1093/jac/dkv385. Epub 2015 Dec 11.

5.

Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database.

Boettiger DC, Nguyen VK, Durier N, Bui HV, Heng Sim BL, Azwa I, Law M, Ruxrungtham K.

J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):186-95. doi: 10.1097/QAI.0000000000000411.

6.

Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.

Katusiime C, Ocama P, Kambugu A.

Afr Health Sci. 2014 Sep;14(3):679-81. doi: 10.4314/ahs.v14i3.25. Review.

7.

Treatment effect and drug-resistant mutations in Chinese AIDS patients switching to second-line antiretroviral therapy.

Zhang M, Shang M, Yang W, Chen J, Wang Z, Shang H.

PLoS One. 2014 Oct 17;9(10):e110259. doi: 10.1371/journal.pone.0110259. eCollection 2014.

8.

Integrase Strand Transfer Inhibitors in HIV Therapy.

Mesplède T, Wainberg MA.

Infect Dis Ther. 2013 Dec;2(2):83-93. doi: 10.1007/s40121-013-0020-8. Epub 2013 Nov 19.

9.

Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length Gag-protease genes.

Sutherland KA, Mbisa JL, Ghosn J, Chaix ML, Cohen-Codar I, Hue S, Delfraissy JF, Delaugerre C, Gupta RK.

J Antimicrob Chemother. 2014 Dec;69(12):3340-8. doi: 10.1093/jac/dku296. Epub 2014 Aug 4.

10.

The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.

Tseng A, Seet J, Phillips EJ.

Br J Clin Pharmacol. 2015 Feb;79(2):182-94. doi: 10.1111/bcp.12403. Review.

11.

HIV Drug Resistance: Problems and Perspectives.

Pennings PS.

Infect Dis Rep. 2013 Jun 6;5(Suppl 1):e5. doi: 10.4081/idr.2013.s1.e5. eCollection 2013 Jun 6. Review.

12.

Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs.

Zhou X, Gao ZW, Meng J, Chen XY, Zhong DF.

Acta Pharmacol Sin. 2013 Nov;34(11):1420-6. doi: 10.1038/aps.2013.76. Epub 2013 Sep 23.

13.

Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance.

Rabi SA, Laird GM, Durand CM, Laskey S, Shan L, Bailey JR, Chioma S, Moore RD, Siliciano RF.

J Clin Invest. 2013 Sep;123(9):3848-60. doi: 10.1172/JCI67399. Epub 2013 Aug 27.

14.

Lack of protease inhibitor resistance following treatment failure--too good to be true?

Bartlett JA.

J Clin Invest. 2013 Sep;123(9):3704-5. doi: 10.1172/JCI71784. Epub 2013 Aug 27.

15.

Crystallographic study of multi-drug resistant HIV-1 protease lopinavir complex: mechanism of drug recognition and resistance.

Liu Z, Yedidi RS, Wang Y, Dewdney TG, Reiter SJ, Brunzelle JS, Kovari IA, Kovari LC.

Biochem Biophys Res Commun. 2013 Jul 26;437(2):199-204. doi: 10.1016/j.bbrc.2013.06.027. Epub 2013 Jun 18.

16.

No clinically significant drug-resistance mutations in HIV-1 subtype C-infected women after discontinuation of NRTI-based or PI-based HAART for PMTCT in Botswana.

Souda S, Gaseitsiwe S, Georgette N, Powis K, Moremedi D, Iketleng T, Leidner J, Moffat C, Ogwu A, Lockman S, Moyo S, Mmalane M, Musonda R, Makhema J, Essex M, Shapiro R.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):572-7. doi: 10.1097/QAI.0b013e31829308f8.

17.

Antiretroviral dynamics determines HIV evolution and predicts therapy outcome.

Rosenbloom DI, Hill AL, Rabi SA, Siliciano RF, Nowak MA.

Nat Med. 2012 Sep;18(9):1378-85.

18.

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

Delaugerre C, Gallien S, Flandre P, Mathez D, Amarsy R, Ferret S, Timsit J, Molina JM, de Truchis P.

PLoS One. 2012;7(5):e36673. doi: 10.1371/journal.pone.0036673. Epub 2012 May 10.

19.
20.

Drug resistance in HIV-1.

Kuritzkes DR.

Curr Opin Virol. 2011 Dec;1(6):582-9. doi: 10.1016/j.coviro.2011.10.020. Review.

Supplemental Content

Support Center